MVX-220

· MavriX Bio, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MVX-220, covering 2026-03-16 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome [Phase 1, Phase 2]